Deflazacort in pediatric rheumatic diseases needs a frequent follow-up of bone densitometry.
Falcini
F
F
Trapani
S
S
Ermini
M
M
Bartolozzi
G
G
D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density; D002648:Child; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced*; D011282:Pregnenediones / Q000009:adverse effects* / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013122:Spinal Diseases / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D011282:Pregnenediones; C021988:deflazacort